LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia

Rationale: Acute myeloid leukemia (AML) is a common type of haematological malignancy. Several studies have shown that neoplasia in AML is enhanced by tyrosine kinase pathways. Recently, given that aberrant activation of Fms-like tyrosine receptor kinase 3 (FLT3) acts as a critical survival signal f...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Zhou, Du, Jiaying, Hui, Hui, Kan, Shaoxin, Huo, Tongxin, Zhao, Kai, Wu, Tao, Guo, Qinglong, Lu, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681098/
https://www.ncbi.nlm.nih.gov/pubmed/33391463
http://dx.doi.org/10.7150/thno.46593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681098/
https://www.ncbi.nlm.nih.gov/pubmed/33391463
http://dx.doi.org/10.7150/thno.46593

Ejemplares similares